APRDL 2012--Explore Innovative Drug Development Models By Tapping Into China’s Market

Over the years, China’s biomedical industry, which comprises biological drugs, medical equipment and materials, and bio-agriculture, has faced a host of problems, including poor financing, a low R&D commercialization rate, and inadequate domestic patent protection. With China’s future expenses for social welfare and health care expected to increase dramatically, the country is placing significant emphasis on developing new medical innovations to help reduce the growth of these costs. Toward that end, the new 12 Five Year’s Plan provides funding for the development and manufacturing of biotech drugs, vaccines, and other innovative drugs used in the prevention and treatment of major diseases. It will also strengthen intellectual property rights, expand R&D, and establish biotech industrial centers, thus opening the door to new investment opportunities. China hopes to become a key player in global drug development by attracting major pharmaceutical companies and research organizations in search of low-cost scientific help and new business with one of the world’s most populous nation.

Join us at fresh Asia Pharma R&D Leaders 2012 where the best minds come together to achieve a joint vision of pharma innovation originated from China. The summit will provide an incredible opportunity to learn more about collaborative models and technologies that enable a revolution in personalized healthcare and health innovation in China. The ground breaking summit programs also provide an incredible opportunity to hear first-hand from our customers how our technologies are revolutionizing medicine, healthcare and even global health policy. Contact Daniel Chen at 8621-52428118 and email to daniel.chen@ for more information.

Asia Pharma R&D Leaders 2012

Date:27th and 29th, November, 2012

Venue: Intercontinental Pudong, Shanghai, China

 

Organizer: Shine Media

Co-organizer: Chinese Pharmaceutical Enterprises Association

 

http://aprdl2012./